 |
NewLink Genetics places substantial focus on the use of its HyperAcute® technology
to develop oncology products. The company currently has four
active Investigational New Drug (IND) applications to pursue
its product development goals and become a leader in the novel,
promising field of cancer vaccines.
|
 |
 |
The Small Molecule Therapeutics division recently filed and IND for its first product candidate IMT, for the treatment of various cancers. We plan to follow and obtain data through two separate Phase-I studies regarding safety and toxicity of the compound.
|
 |
 |
2901 South Loop Drive
Suite 3900
Ames, Iowa 50010
Phone: 515-296-5555
Fax: 515-296-5557
|
 |
|